

Background

As peptides become increasingly more prevalent as therapeutic options, it has become essential to achieve greater separation and identify difficult to resolve impurities. 2D-LC offers much greater levels of resolution by allowing peaks in the 1st dimension to be further separated in the 2nd dimension. The following case study presents the analytical workflow used to identify an unknown peak, closely eluting in the tail of an API peak, using a 2D-LC system coupled to a Q-TOF mass spectrometer.

Analytical Equipment

Analysis was performed using an Agilent 1290 Infinity II 2D-LC system coupled with an Agilent Accurate Mass 6530 Q-TOF Mass Spectrometer (Figure 1). Agilent OpenLab ChemStation software was used to take a fraction (known as a heartcut) of the impurity and Agilent MassHunter software with BioConfirm was used for amino acid sequencing.




Figure 1: Agilent 1290 Infinity II 2D-LC (left) and Agilent Accurate Mass 6530 Q-TOF (right).

LC-MS and LC-MS/MS Analysis

LC-MS was initially used to try and determine the accurate mass of the API and the impurity in the tail of the API. The impurity was observed to have the same mass as the API. Fragmentation data was then generated by LC-MS/MS (Figure 2) to determine the identity of the impurity. The sequence map of the fragments present within the impurity matched with the API. However, during precursor selection, the software could not separately identify the peaks, so the level of contribution of API ions to the fragmentation profile of the impurity could not be assessed.

